<DOC>
	<DOCNO>NCT00707980</DOCNO>
	<brief_summary>The purpose study determine long-term efficacy safety vortioxetine , daily ( QD ) , adult major depressive disorder .</brief_summary>
	<brief_title>Safety Tolerability Vortioxetine ( Lu AA21004 ) Adults With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call vortioxetine . Vortioxetine test treat depression people major depressive disorder ( MDD ) . This study look MDD relief people take vortioxetine . The study enrol 836 patient complete one two vortioxetine study . Participants receive 5 mg vortioxetine first week treatment . After complete first week treatment , dose could increase 10 mg/day decrease 2.5 mg/day base participant 's response judge doctor . All participant ask take one encapsulate tablet time day throughout study . This multi-center trial conduct worldwide . The overall time participate study 56 week . Participants make 13 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Has complete double blind treatment period either study Lu AA21004_304 ( NCT00672620 ) LuAA21004_305 ( NCT00735709 ) immediately prior enrollment extension study ( ie , baseline visit visit completion visit double blind treatment precede protocol ) . Suffers major depressive episode primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.xx ) entry prior Lu AA21004_304 Lu AA21004_305 study . In addition meeting exclusion criterion study Lu AA21004_304 Lu AA21004_305 time enrollment study respectively , exception criterion prohibit previous exposure Lu AA21004 investigational drug , criterion prohibit patient increase intraocular pressure , risk acute narrowangle glaucoma , follow exclusion criterion apply : Has Major Depressive Disorder psychiatric disorder ( mania , bipolar disorder , schizophrenia , psychotic disorder ) diagnose prior study . The participant , investigator 's opinion , significant risk suicide and/or score ≥5 point item 10 ( suicidal thought ) Montgomery Åsberg Depression Rating Scale . The participant , opinion investigator , unlikely comply clinical study protocol unsuitable reason . Has clinically significant moderate severe ongoing adverse event relate study medication prior study . Has used/uses disallow concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Melancholia</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Dysthymic Disorder</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>